R&D Pipeline

R&D Pipeline Pipeline (2021-2030)

Pipeline (2021-2030)

Immunology - Small molecules (36)

Modality Indication Targets Stage Company Project No. Detail
1 Development of highly selective STAT3 allosteric inhibitors as oral IBD therapies to overcome the limitations of existing treatments
Small molecules IBD STAT3 Candidate Huchembio Co., Ltd. RS-2026-25503669
2 **** inhibitor substance-based systemic lupus erythematosus new drug candidate substance development
Small molecules Systemic lupus erythematosus **** Candidate PROVIBIO RS-2026-25503404
3 Discovery of small-molecule drug candidates for the treatment of Fibrostenotic Crohn's Disease
Small molecules FSCD TG2 Candidate Huons RS-2026-25503256
4 Discovery of a First-in-Class Oral Small-Molecule TL1A Inhibitor for Inflammatory Bowel Disease
Small molecules IBD TL1A Candidate ILAb Co., Ltd. RS-2026-25501736
5 Establishing a Clinical Trial Basis Through Nonclinical Evaluation of CR-C003, a First-in-Class Drug Candidate for the Treatment of Inflammatory Bowel Disease
Small molecules Inflammatory Bowel Disease (IBD); Ulcerative Colitis (UC) and Crohn's Disease (CD) CR-E1 (Code name) Preclinical CUROGEN Technology RS-2025-25455442
6 Preclinical Study of a Novel BBB penetrant drug for Multiple Sclerosis
Small molecules Multiple Sclerosis **** Preclinical Daewoong Pharmaceutical RS-2025-25455086
7 Development of mPGES-1 targeted anti-inflammatory mechanism-based arthritis and pain treatment
Small molecules inflammation and pain-related disorders mPGES-1 Preclinical Kukje pharma RS-2025-25454561
8 Non-clinical study of OM202-001 from NSDC platform for the treatment of Autoimmune diseases
Small molecules Ulcerative colitis JAK1 Preclinical Omniamed RS-2025-02223486
9 Discovery of lead compounds for multiple sclerosis via inflammation modulation induced by PKM2 tetramerization
Small molecules Multiple sclerosis PKM2 Lead Hanyang University ERICA RS-2025-02223325
10 Development of Selective TYK2 Allosteric Domain Inhibitors as Candidate Therapeutics for Autoimmune Diseases
Small molecules Inflammatory autoimmune disease TYK2 Candidate AZothBio, Inc. RS-2025-02213331
11 Development of an oral EGR1-targeted candidate for atopic dermatitis
Small molecules Atopic dermatitis EGR-1 Candidate AgeraMedi, INC. RS-2025-02213190
12 Phase 1 development of Axl, Mer, CSF1R inhibitor Q702
Small molecules cGVHD Axl, Mer, CSF1R Phase 1 Qurient Co., Ltd. RS-2025-02213024
13 Development of Selective STAT6 Inhibitors for Eosinophilic Esophagitis and Th2 Inflammatory Immune Diseases
Small molecules EoE, Type 2 inflammatory autoimmune disease STAT6 Candidate JW C&C Research Laboratories RS-2025-02183026
14 Preclinical Candidate Development of Innovative Drugs Targeting NLRP3 Inflammasome Inhibition for Inflammatory Bowel Disease
Small molecules Ulcerative colitis NLRP3 Candidate JMackem Co., Ltd RS-2025-02173120
15 Novel Oral Therapeutic Candidate for the Treatment of Chronic Urticaria
Small molecules Chronic Urticaria MRGPRX2 Preclinical Samjin Pharm. Co., Ltd. RS-2025-02173007
16 Development of LCN2 inhibitor for multiple sclerosis
Small molecules Multiple sclerosis Lipocalin 2 (LCN2) Hit K-MEDI hub RS-2024-00335752
17 Developing the drug candidates for psoriasis treatment using small molecule with IRAK.1/4 inhibition
Small molecules Psoriasis IRAK1/4 Candidate Dongwha Pharm Co.,Ltd. RS-2023-00284094
18 Development of a novel RIPK1 inhibitor for autoimmune disease(BSC.1300)
Small molecules Autoimmune diseases RIPK1 Candidate BiSiChem RS-2023-00259271
19 Development of a novel topical treatment for atopic dermatitis by modulating TSLP signaling
Small molecules Atopic dermatitis TSLP/TSLPR Preclinical AmtixBio RS-2023-00258738
20 Development of a therapeutic agent for ulcerative colitis based on the regeneration mechanism of intestinal mucosa using an AIbased drug development platform
Small molecules Ulcerative colitis 15.PGDH Candidate Innovo Therapeutics, Inc. RS-2023-00258490
21 Completion of non-clinical studies and IND authorization for a 3rd generation multiple sclerosis drug candidate based on biased modulation that overcomes the limitations of cardiac side effects
Small molecules Multiple Sclerosis S1P1 Preclinical CUREVERSE RS-2023-00217346
22 Development of Hit/Lead compound using PKCη inhibitory drugs for treating multiple sclerosis
Small molecules Multiple Sclerosis PKCη Hit Hanyang University RS-2023-00217324
23 Development of functional hyaluronic acid nanoparticle lead compounds for treatment of skin inflammation
Small molecules Psoriasis Cannabinoid 1 receptor Hit Ajou University RS-2023-00217308
24 Development of STAT6 blocking therapeutic drug in systemic sclerosis with targeting profibrotic T cells and fibroblasts
Small molecules Systemic Sclerosis STAT6 Hit The catholic university, medical college, LaTIM (Lab of Translational ImmunoMedicine) RS-2023-00217274
25 Development of a therapeutic agent for ulcerative colitis by regulating glycogen metabolism of
 immune cells and intestinal epithelial cells
Small molecules Ulcerative Colitis PYGL Phase 1 INNOVO Therapeutics RS-2022-00166802
26 Clinical development of a novel synthetic AHR agonist PB542 as an IBD therapeutics
Small molecules Crohn's disease AhR Preclinical Parenchyma Biotech RS-2022-00165759
27 Discovery of Leads as LRRK2 inhibitors for the treat of Crohn’s disease
Small molecules Crohn's disease LRRK2 Lead Chung Ang University HN22C0690
28 Discovery of Lead for a First-in-Class Drug Treating Inflammatory Bowel Disease (IBD)
Small molecules Ulcerative colitis, Crohn's disease PIN1 Lead PimedBio HN22C0056
29 Discovery of non-clinical candidates of new PKM2 activator that cure inflammation and fibrosis at the same time through cell metabolism modulation
Small molecules Rheumatoid arthritis, IBD PKM2 Candidate Lmito Therapeutics HN21C0943
30 Development of a therapeutic agent for ulcerative colitis by regulating glycogen metabolism of immune cells and intestinal epithelial cells
Small molecules Ulcerative colitis PYGL Preclinical INNOVO Therapeutics HN21C0604
31 The generation of candidate for atopic dermatitis via selective STAT3 inhibition
Small molecules Atopic dermatitis STAT3 Candidate C&C Research Laboratories HN21C0543
32 Development of anti-fibrosis therapeutics for systemic sclerosis using SOS1- RAS interaction-specific blockade
Small molecules Systemic Sclerosis SOS1/RAS Hit Kyungpook National University HN21C0307
33 Discovery study of CR-E1 targeting psoriasis lead compounds by regulating Th17 mechanism
Small molecules Psoriasis CR-E1 Hit Curogen Technology HN21C0250
34 Discovery of lead small molecules to control NLRP3 inflammasome
Small molecules Psoriasis, Inflammatory disease NLRP3 Lead Ajou University HN21C1058
35 Development of SCED-based lead compounds for atopic dermatitis
Small molecules Atopic dermatitis EGR1 Hit Konkuk University HN21C0984
36 Development of TYK2 pseudokinase domain selective inhibitor for autoimmune treatment
Small molecules Psoriasis, Rheumatoid Arthritis Tyk2 Lead CrystalGenomic Inc. HN21C0189
BACK